Enthesitis precedes the onset of PsA in PsO patients. Dr. @lihi_eder discusses the importance of US in evaluation of these patients. #RNL2024 @RheumNow https://t.co/bPLR7zpNe2

Thank you to all of the excellent #RNL2024 speakers! @Bweber04, Dr. Monica Guma, Dr. Hani Gabalawy, Dr. Connie Weyand, Dr. Lisa Stamp, @AlexisOgdie, @_AprilArmstrong, @lihi_eder, @JointMD, Dr. Kevin Winthrop, Dr. Bruce Strober, @BharatKumarMD, Dr. David Karp, @Kahlenberglab,… https://t.co/f6gzCwe7Xb https://t.co/2SY9mPqdkO

AS v nr-AxSpA for TNFi - no diff in response @JointMD @RheumNow #RNL2024 ADA: ASAS20 AS 58%, nr-AxSpA 52%, ASAS40 AS 39%, nr 36% (ATLAS, ABILITY-1) ETN: ASAS 20 59%/52%, ASAS50/40 44%/33% in p3 AS study v EMBARK CZP: RAPID-AxSpA - no diff bw AS & nr-AxSpA response in same trial https://t.co/Rau2CDYbY4

The ultimate treatment goal in LN is long term preservation of kidney function. Summary of part 3 of @andreafava brilliant talk. #RNL2024 @RheumNow https://t.co/vwiAbWEmRh

Very insightful talk on Vasculitis and pregnancy by Catherine Sims. Pregnancy compatible medications. Remission state. Checking antibodies ; risk of transmission, pregnancy and fetal morbidity. #RNL2024 @RheumNow https://t.co/81NAN1ulO5

#RNL2024 @RheumNow @JointMD on AxSpA SPEED study: roughly 1/2 AS have AxSpA, 1/2 have nr-AxSpA Are they similar: - Yes, but r-axSpA less F and more abnml CRP = Low progression of nr-AxSpA to AS - only 26% progressed in mean 10.6 yrs https://t.co/Vwf5HaMcgu

We all want to preserve kidney function in lupus nephritis and to have good none invasive method to do that is just great. Low IL-16 at 12 months predicted kidney survival at 3 years better than proteinuria. 👏 @andreafava and his team. #RNL2024 @RheumNow https://t.co/O0trWoAqZz

Urine biomarkers ( IL-16, CD163,CD206), parallel internal activity in lupus nephritis and and its decline at 3 months , best predict 1 year response . Future is great for lupus nephritis , cant wait to start using them. Great work @andreafava #RNL2024 @RheumNow https://t.co/VIFMytHFyD

Urine proteomics in lupus nephritis. Summary of part one of his amazing talk. @andreafava #RNL2024 @RheumNow https://t.co/h8Eda0ZWVE

Neutrophil signature in proliferative lupus nephritis. @andreafava #RNL2024 @RheumNow https://t.co/tNFIhohSvP

Cancer and Myositis #RNL2024 @RheumNow @DrLisaCS on Cancer screening: Risk stratify: dermatomyositis, NXP2, TIFy, <40yo, refractory, dysphagia, cutaneous necrosis at higher risk Enhanced risk stratification for those at risks, versus "basic screening" for lower risks https://t.co/3yy9Fx1pk8